Abcam Plc (ABC) Price Target Raised to GBX 946
Abcam Plc (LON:ABC) had its target price lifted by J P Morgan Chase & Co from GBX 864 ($11.65) to GBX 946 ($12.75) in a research note issued to investors on Monday morning, StockTargetPrices.com reports. The firm currently has a neutral rating on the stock.
A number of other brokerages also recently commented on ABC. Peel Hunt reaffirmed a hold rating and set a GBX 750 ($10.11) target price on shares of Abcam Plc in a research note on Friday, August 18th. Berenberg Bank reissued a buy rating and issued a GBX 1,100 ($14.83) price target on shares of Abcam Plc in a research note on Monday, September 11th. Panmure Gordon reissued a sell rating on shares of Abcam Plc in a research note on Monday, September 11th. Finally, Numis Securities Ltd lifted their price objective on shares of Abcam Plc from GBX 1,116 ($15.05) to GBX 1,200 ($16.18) and gave the company an add rating in a report on Tuesday, September 12th. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of GBX 972.67 ($13.11).
Shares of Abcam Plc (ABC) opened at 1023.00 on Monday. The stock’s market capitalization is GBX 2.08 billion. The stock’s 50 day moving average is GBX 1,056.46 and its 200 day moving average is GBX 959.01. Abcam Plc has a 12 month low of GBX 759.50 and a 12 month high of GBX 1,113.00.
In other Abcam Plc news, insider Louise Patten purchased 1,636 shares of Abcam Plc stock in a transaction that occurred on Thursday, September 14th. The stock was purchased at an average price of GBX 1,079 ($14.55) per share, for a total transaction of £17,652.44 ($23,799.97).
Abcam Plc Company Profile
Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company’s purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways.
Receive News & Stock Ratings for Abcam Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam Plc and related stocks with our FREE daily email newsletter.